Yet another potentially profitable play regarding the Covid-19 pandemic is MRNA, A pharmaceutical company that is currently entering its 3rd phase of a corona Vaccine. While this play depends largely on its vaccine success over the rest of the month this could be an extremely lucrative play. It has been in a consolidation zone for the past few weeks, a Good buy in level is at $61-$63 and because of its heavy reliance on the performance of its vaccine to remain profitable I am keeping a tight stop loss. Anything over a 10% drop presents to much risk to feasibly call it worthwhile.
Beyond Technical AnalysisCoronavirus (COVID-19)covid-2019pharmaceuticalsvaccine

Disclaimer